Status:
COMPLETED
Mechanisms and Biomarkers for Tumor Immunogenicity Modulation in Cervical Cancer
Lead Sponsor:
Chuangzhen Chen
Conditions:
Cervical Cancer
Benign Tumor of Uterus
Eligibility:
All Genders
Brief Summary
This study aims to investigate mechanisms that dictate tumor immunogenicity and to explore potential biomarkers that could help predict changes of tumor immunogenicity and therapeutic response in pati...
Detailed Description
Patients pathologically confirmed with cervical cancer or benign gynecologic tumor that requires chemoradiotherapy or surgery will be recruited to this study. Tumor samples, normal epithelium of the c...
Eligibility Criteria
Inclusion
- Pathological proven diagnosis of cervical cancer or benign gynecologic tumor and will undergoing panhysterectomy or pathological proven diagnosis of cervical cancer and will undergoing radiotherapy
- Tumor accessible for biopsy during the course of radiotherapy or tumor samples could be obtained via surgery
- Patient must provide study-specific informed consent prior to study entry
Exclusion
- History of autoimmune diseases
- History of immunotherapy
- History of pelvic radiotherapy
- Will receive immunotherapy during the course of treatment
- Contraindications for biopsy, such as high bleeding risk
Key Trial Info
Start Date :
December 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 15 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05188716
Start Date
December 10 2020
End Date
January 15 2022
Last Update
February 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China, 515031